中國科學(xué)院大學(xué)附屬腫瘤醫(yī)院（浙江省腫瘤醫(yī)院）王曉稼課題組博士后招聘啟事

中國科學(xué)院大學(xué)附屬腫瘤醫(yī)院（浙江省腫瘤醫(yī)院）乳腺腫瘤內(nèi)科王曉稼主任在研項(xiàng)目匯總

歷史回顧丨新一代多基因模型預(yù)測(cè)亞裔早期激素敏感型乳腺癌患者術(shù)后10年遠(yuǎn)處轉(zhuǎn)移風(fēng)險(xiǎn)的驗(yàn)證性研究（2019SABCS）

歷史回顧丨亞裔多基因預(yù)測(cè)復(fù)發(fā)風(fēng)險(xiǎn)模型（2019ASCO）

Lancet Oncol Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial Xiaojia Wang (2015)

Oncotarget Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China Xiaojia Wang (2016)

Oncotarget Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study Xiaojia Wang (2016)

Breast Cancer Res Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1 Xiaojia Wang (2017)

Lancet Oncol Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial Xiaojia Wang (2017)

Eur J Cancer Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial Xiaojia Wang (2019)

Lancet Oncol Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial Xiaojia Wang (2019)

Invest New Drugs Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial Xiaojia Wang (2020)

Breast Cancer Res Treat Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study  Xiaojia Wang (2020)

Adv Med Oncol MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study Xiaojia Wang (2020)

Lancet Oncol Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial Xiaojia Wang (2021)